Notably, GZMK-expressing CD8+ T cells are positively correlated with the response to immunotherapy in clear cell renal cell carcinoma [38], esophageal cancer [37], and peripheral blood of non-small cell lung cancer patients [39]. This evidence concerns the gene GZMK and non-small cell lung carcinoma.